QPS CEO Ben Chien has made it through to the round of 30 (31, actually) being considered for this year’s prestigious EY Entrepreneur Of The Year Award for the Greater Philadelphia area. The only competitive awards program in the world for entrepreneurs and leaders of high-growth companies, the 30 year-old program operates in 145 cities …
QPS Aids Development of Cannabinoid Chewing Gum, for MS Patients
Cannabinoid bioscience has come a long way. New York-based Axim Biotech is at the forefront, developing – among many other, related products – a multi-layered, slow-release cannabinoid chewing gum. Not for the candy stand, MedChewRx® is seeking FDA and EMA approval for the treatment of pain and spasticity associated with multiple sclerosis. Characteristically, QPS is …
Fast Track Routes for Medicines that address Unmet Medical Needs
Launch of two-month public consultations on revised guidelines on accelerated assessment and conditional marketing authorization The European Medicines Agency (EMA) has revised its guidelines on the implementation of accelerated assessment and conditional marketing authorization, two key tools in the European legislation to accelerate patients’ access to medicines that address unmet medical needs. Accelerated assessment and …
Regulatory Expertise Now Part of QPS Clinical Development Offerings
In July 2015, regulatory expert Patricia Baede joined QPS’ clinical development teams. With 20 years of experience in clinical trial conduct and all regulatory aspects of drug development, Baede adds EU regulatory support to the growing portfolio of clinical activities QPS provides. In the past, she has worked on drug development teams as Phase I …